In a first for the neurotoxin market, Ipsen announced Thursday that its Dysport has hit the goals in two phase 3 trials for the prevention of both episodic and chronic migraines. While AbbVie’s market ...
Pharmaceutical Technology on MSN
Ipsen set to rival Botox after duo of Phase III migraine wins
The company claims that Dysport is now the first botulinum toxin therapy to demonstrate efficacy in episodic migraine.
InStyle on MSN
The makers of Botox created a peptide-packed eye cream that firms crepey, post-menopausal skin, per fans
Shoppers in their 60s call it “excellent for aging skin.” ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results